Biolinq has completed its pivotal trial and submitted its wearable biosensor to the FDA for regulatory review.

The Series C funding supports Biolinq’s transition from development stage to commercial readiness following US pivotal trial ...

Biolinq has secured $100m in Series C funds to support the regulatory approval process in the US to launch its intradermal ...

Innovative catalyst design enhances CO2 reduction efficiency by stabilizing the *COOH intermediate, revealing the impact of microenvironment on catalysis.

SAN DIEGO – Biolinq, a healthcare technology company of biosensors, has received a $100 million Series C financing led by Alpha Wave Ventures ...

Maintaining profitability amid considerable uncertainty in global trade, environmental policy and product demand is a ...

Copper is the most promising catalyst for turning carbon dioxide into valuable chemical feedstocks and liquid fuels through ...

Biolinq received $100 million in a Series C funding round to bring its wearable for patients with diabetes to market, the company said Tuesday.